The neuromuscular junction consists of three anatomically distinct zones. The presynaptic motor nerve terminal is the expanded, unmyelinated ending of a lower motor neuron. It is packed with synaptic vesicles, each containing several thousand molecules of acetylcholine. The synaptic cleft is the narrow gap between the nerve terminal and the muscle membrane, roughly 20 to 50 nanometers wide. Within the cleft, acetylcholinesterase is anchored at high density and terminates acetylcholine signaling within milliseconds of receptor activation. The postsynaptic membrane — the motor end plate — is thrown into deep folds that increase its surface area and concentrate nicotinic acetylcholine receptors at the peaks of those folds, directly opposite the nerve terminal active zones.

This spatial organization is pharmacologically relevant. Nondepolarizing neuromuscular blocking drugs compete with acetylcholine at the postsynaptic receptor. Reversal agents that inhibit acetylcholinesterase increase acetylcholine concentration in the cleft, allowing it to displace the blocking drug from the receptor. The geometry of the junction — with acetylcholinesterase positioned to intercept acetylcholine molecules and receptors clustered at the end plate — sets the competitive playing field that determines drug effect.

Under normal conditions, nicotinic acetylcholine receptors are concentrated almost exclusively at the motor end plate and are not expressed across the broader surface of the muscle fiber. This distribution changes under pathological conditions — particularly denervation, prolonged immobilization, burns, and crush injury. In these states, the muscle upregulates a fetal isoform of the nicotinic receptor across the extrajunctional membrane surface. These extrajunctional receptors have altered channel properties: they open more readily in response to depolarizing stimuli and close more slowly, allowing prolonged potassium efflux. The clinical consequence is exaggerated hyperkalemia when succinylcholine is administered to patients with these conditions, a phenomenon detailed in Module 2.

Acetylcholine is synthesized in the nerve terminal from two precursors: choline, which is actively transported into the terminal from the extracellular space, and acetyl coenzyme A, which is derived from mitochondrial metabolism. The enzyme choline acetyltransferase catalyzes the condensation of these two substrates to form acetylcholine. Once synthesized, acetylcholine is packaged into synaptic vesicles by a dedicated vesicular transporter and stored until a nerve impulse arrives.

When an action potential reaches the nerve terminal, voltage-gated calcium channels in the presynaptic membrane open, allowing calcium to flow into the terminal down its concentration gradient. The rise in intracellular calcium triggers fusion of acetylcholine-containing vesicles with the presynaptic membrane — a process of exocytosis — releasing acetylcholine into the synaptic cleft in discrete quantal packets. The calcium dependence of this release step explains why drugs that reduce presynaptic calcium entry, such as aminoglycoside antibiotics and magnesium, can impair neuromuscular transmission and potentiate the effect of nondepolarizing blocking drugs.

Once acetylcholine diffuses across the cleft and binds to nicotinic receptors, it is released and rapidly hydrolyzed by acetylcholinesterase into choline and acetate. The choline is taken back up into the nerve terminal and recycled into new acetylcholine synthesis. Acetylcholinesterase operates at extraordinary speed — it can hydrolyze tens of millions of acetylcholine molecules per minute — ensuring that each nerve impulse produces a brief, precisely timed end-plate potential rather than sustained depolarization.

Drugs that inhibit acetylcholinesterase — the anticholinesterase agents neostigmine and pyridostigmine — extend the residence time of acetylcholine in the cleft by preventing its hydrolysis. This is the pharmacological basis of reversal for nondepolarizing neuromuscular block: the elevated acetylcholine concentration competes with the blocking drug at the nicotinic receptor, gradually restoring transmission. This reversal strategy is examined in detail in Module 4.

The neuromuscular nicotinic acetylcholine receptor is a pentameric ligand-gated ion channel — five protein subunits arranged around a central ion-conducting pore. Critically, the receptor has two acetylcholine binding sites, and both must be occupied simultaneously for the channel to open. This dual-site requirement has pharmacological significance: a single molecule of a competitive antagonist occupying one of the two sites is sufficient to prevent channel opening, even if the other site is occupied by acetylcholine.

When both sites are occupied by acetylcholine, the channel opens and allows cation flow: sodium moves inward, potassium moves outward, and the net effect is a rapid depolarization of the end-plate membrane called the end-plate potential. This local depolarization then activates voltage-gated sodium channels in the surrounding muscle membrane, generating an action potential that propagates along the fiber and triggers contraction.

A normal neuromuscular junction operates with a substantial safety margin. Under physiological conditions, the end-plate potential is roughly three to four times larger than the minimum amplitude needed to trigger a muscle action potential. This excess amplitude means that a large fraction of nicotinic acetylcholine receptors can be blocked without producing any measurable weakness. Experimental studies suggest that approximately 70 to 80 percent of receptors must be occupied by a nondepolarizing blocking drug before peak twitch strength begins to fall, and 90 to 95 percent must be occupied before the patient cannot sustain a tetanic contraction.

This safety margin has important clinical implications. Train-of-four monitoring — the standard clinical tool for assessing depth of block — detects progressive loss of this margin. The safety margin is also eroded by disease. In myasthenia gravis, autoantibodies destroy nicotinic acetylcholine receptors, reducing receptor density by 70 to 80 percent in some patients. These patients begin with a much smaller safety margin and are therefore exquisitely sensitive to nondepolarizing neuromuscular blocking drugs; even small doses can produce prolonged and profound block. The reverse logic applies to succinylcholine: fewer available receptors means succinylcholine must reach a greater proportion of them to produce depolarization, so myasthenia gravis patients may show partial resistance to the depolarizing agent.

Nondepolarizing neuromuscular blocking drugs — which include the large majority of agents in clinical use — act as competitive antagonists at the nicotinic acetylcholine receptor. They bind to one or both of the acetylcholine binding sites on the receptor without activating it, physically preventing acetylcholine from binding and opening the channel. The muscle membrane remains at its resting potential: no depolarization occurs, no action potential is generated, and the muscle does not contract. Because the block is competitive, it can be overcome by increasing the concentration of acetylcholine in the cleft — which is exactly what anticholinesterase reversal agents do.

Nondepolarizing block produces no fasciculations before the onset of paralysis. The patient transitions smoothly from normal muscle tone to flaccid paralysis. On train-of-four stimulation, nondepolarizing block produces a characteristic fade pattern: the fourth twitch in the sequence is weaker than the first, because each successive stimulus depletes the releasable pool of acetylcholine and reduces the receptor-occupying competition for the blocking drug. The depth of block is graded by the magnitude of this fade.

Succinylcholine, the sole depolarizing neuromuscular blocking drug in clinical use, works by a completely different mechanism. Rather than blocking the receptor, succinylcholine activates it — it is an acetylcholine receptor agonist. Unlike acetylcholine, however, succinylcholine is not rapidly hydrolyzed by acetylcholinesterase. It persists in the cleft, maintaining continuous receptor activation and holding the end-plate membrane in a depolarized state.

The initial binding of succinylcholine to the receptor opens ion channels, producing a brief depolarization of the end-plate membrane. This depolarization propagates as action potentials along the muscle fiber, causing the visible and palpable muscle fasciculations that characterize succinylcholine administration. After the initial fasciculations subside, the membrane remains persistently depolarized and cannot respond to subsequent nerve impulses. The voltage-gated sodium channels adjacent to the end plate, which require repolarization before they can reopen, remain inactivated — and the muscle falls into a sustained, flaccid paralysis despite the continued presence of acetylcholine receptor activation at the end plate. This is called phase I block.

With prolonged or repeated succinylcholine dosing, the character of the block can shift — the end-plate membrane partially repolarizes and the receptor undergoes a conformational change to a desensitized state. This phase II block resembles nondepolarizing block in its train-of-four characteristics and may be partially reversible with anticholinesterase agents, though this is unpredictable.